Table 2

Characteristics of patients with newly diagnosed type 2 diabetes enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project during November 2010–February 2016

VariablesPatients with type 2 diabetes
Persons enrolled in DD2 by February, 2016, n (%) 7011 (100)
  Enrolled from general practitioners’ offices, n (%)3688 (53)
  Enrolled from hospital clinics, n (%)3323 (47)
Median age (IQR), years61 (52–68)
Minimum–maximum age, years17–95
Gender, n (%)
  Male4065 (58)
  Female2946 (42)
Resting heart rate, median (IQR)70 (63–79)
Waist circumference, median
(IQR), cm
106 (97–116)
Waist–hip ratio in men, median (IQR)1.02 (0.97–1.06)
Waist–hip ratio in women, median (IQR)0.92 (0.87–0.97)
Median weight at 20 years of age (IQR), kg70 (60–80)
  Weight unknown at age 20, n (%)929 (13)
Median maximum lifetime weight (IQR), kg100 (86–115)
  Maximum lifetime weight unknown, n (%)75 (1)
Alcohol use, n (%)
  Maximum 14/21 drinks/week (women/men)6539 (93)
  More than 14/21 drinks/week (women/men)472 (7)
Days per week with 30+ min of physical activity (days)
  01161 (17)
  1488 (7)
  2891 (13)
  3954 (14)
  4622 (9)
  5681 (10)
  6317 (5)
  71897 (27)
Regular sports activities, n (%)
  Yes2748 (39)
  No4262 (61)
Level of physical activity during the past year, n (%)
  Hard physical training and competitive sports several times a week55 (1)
  Leisure sports, heavy garden work or similar activity at least 4 hours per week1370 (20)
  Walking, cycling or other light exercise at least 4 hours per week4298 (61)
  Reading, television watching or other sedentary activity1288 (18)
Family history of diabetes, n (%)
  Yes3717 (53)
  No2696 (39)
  Don’t know598 (9)
Median fasting blood glucose (IQR), mmol/L*7.1 (6.4–8.3)
Median C-peptide†‡ (IQR), pmol/L1161 (865–1570)
Glutamic acid decarboxylase antibodies§
 ≤30 kU/L, N (%)5655 (97)
 >30 kU/L, N (%)161 (3)
Median alanine-aminotransferases¶ (IQR), U/L27 (20–38)
Median pancreatic amylase¶ (IQR), U/L23 (16–30)
Median C reactive protein¶ (IQR), mg/L2.1 (1.0–4.8)
  • *Currently analysed for the first consecutive 5363 DD2 patients.

  • †Reference range: 400–1600 pmol/L.

  • ‡Currently analysed for the first consecutive 5800 DD2 patients.

  • §Currently analysed for the first consecutive 5816 DD2 patients.

  • ¶Currently analysed for the first consecutive 1018 DD2 patients.